History: (Revisor's note: In codifying this section the Revisors editorially changed two references in Subsec. (b) from
"pharmacists" to "pharmacist" for consistency); P.A. 03-164 amended Subsec. (a) by designating existing provisions as
Subdiv. (1), making a technical change therein, and adding Subdiv. (2) allowing pharmacists employed by nursing home
facilities to enter into collaborative drug therapy management agreement, and made conforming changes in Subsec. (c);
June 30 Sp. Sess. P.A. 03-6 and P.A. 04-169 replaced Commissioner and Department of Consumer Protection with Commissioner and Department of Agriculture and Consumer Protection, effective July 1, 2004; P.A. 04-189 repealed Sec. 146 of
June 30 Sp. Sess. P.A. 03-6, thereby reversing the merger of the Departments of Agriculture and Consumer Protection,
effective June 1, 2004; P.A. 05-217 amended Subsec. (a) by adding Subdiv. (3) allowing hospital pharmacists to enter into
collaborative drug therapy management agreements to manage drug therapy of patients receiving outpatient hospital care
or services for diabetes, asthma, hypertension, hyperlipidemia, osteoporosis, congestive heart failure or smoking cessation.
Sec. 20-631a. Collaborative drug management agreements between pharmacists employed by community pharmacies and one or more physicians. Pilot program. (a) Not later than January 1, 2006, the Commissioner of Consumer Protection,
in consultation with the Commission of Pharmacy, shall establish and operate a two-year pilot program to allow not more than ten pharmacists licensed under this chapter
who are determined eligible in accordance with subsection (c) of this section and employed by or under contract with a licensed community pharmacy, to enter into a written
protocol-based collaborative drug therapy management agreement with one or more
physicians licensed under chapter 370, to manage the drug therapy of individual patients
receiving drug therapy for diabetes, asthma, hypertension, hyperlipidemia, osteoporosis,
congestive heart failure or smoking cessation, including patients who qualify as targeted
beneficiaries under the provisions of Section 1860D-4(c)(2)(A)(ii) of the federal Social
Security Act, in accordance with subsections (b) to (d), inclusive, of this section and
subject to the approval of the licensed community pharmacy. Each patient's collaborative drug therapy management shall be governed by a written protocol specific to that
patient established by the treating physician in consultation with the pharmacist.
(b) A collaborative drug therapy management agreement may authorize a pharmacist to implement, modify or discontinue a drug therapy that has been prescribed for a
patient, order associated laboratory tests and administer drugs, all in accordance with a
patient-specific written protocol. Each protocol developed, pursuant to the collaborative
drug therapy management agreement, shall contain detailed direction concerning the
actions that the pharmacist may perform for that patient. The protocol shall include, but
need not be limited to, (1) the specific drug or drugs to be managed by the pharmacist,
(2) the terms and conditions under which drug therapy may be implemented, modified
or discontinued, (3) the conditions and events upon which the pharmacist is required to
notify the physician, and (4) the laboratory tests that may be ordered. All activities
performed by the pharmacist in conjunction with the protocol shall be documented in
the patient's medical record. The pharmacist shall report to the physician through oral,
written or electronic manner regarding the implementation, administration, modification or discontinuation of a drug therapy that has been prescribed for a patient not later
than twenty-four hours after such implementation, administration, modification or discontinuation. The collaborative drug therapy management agreement and protocols
shall be available for inspection by the Departments of Public Health and Consumer
Protection. A copy of the protocol shall be filed in the patient's medical record.
(c) In order to be selected for participation in the program, a pharmacist shall be
responsible for demonstrating, in accordance with this subsection, the competence necessary for participation in each drug therapy management agreement into which such
pharmacist may enter. The pharmacist's competency shall be determined by the Commission of Pharmacy using criteria based on the continuing education requirements of
sections 20-599 and 20-600.
(d) The Commissioner of Consumer Protection and the Commission of Pharmacy
shall evaluate the pilot program established under this section and shall submit a report
of the commissioner's findings and recommendations to the joint standing committees
of the General Assembly having cognizance of matters relating to public health, human
services and general law, not later than December 31, 2008, in accordance with the
provisions of section 11-4a. Such report shall include an evaluation of the data collected
with respect to improved medication management and cost savings, based on patient
outcomes.
(e) Records or information collected or maintained pursuant to this section shall
not be disclosed pursuant to subsection (a) of section 1-210 for a period of six months
from the date such records or information were created or collected and shall not be
subject to subpoena or discovery or introduced into evidence in any judicial or administrative proceeding except as otherwise specifically provided by law.
(f) For purposes of this section, "community pharmacy" means a pharmacy licensed
under section 20-594 that stores and dispenses legend drugs, as defined by section 20-571, and legend devices, as defined by said section 20-571, and from which related
pharmaceutical care services are provided, primarily to noninstitutionalized patients
living in a community setting.
(P.A. 05-217, S. 2.)
History: P.A. 05-217 effective July 6, 2005 (Revisor's note: The subsection designator "a" was inserted editorially by
the Revisors at the beginning of the section).
Sec. 20-632. Regulatory action report re disciplinary action against persons
with controlled substance registrations and sanctions against pharmacists or pharmacies. Not less than once every three months, the Department of Consumer Protection
shall compile a regulatory action report that contains information regarding: (1) Any
disciplinary action taken by the department against any person with a controlled substance registration, and (2) any sanction by the Commission of Pharmacy against a
pharmacy or pharmacist. Such report shall contain the reasons for any such action or
sanction and shall be posted on the web site of the department.
(P.A. 05-212, S. 5.)
History: P.A. 05-212 effective July 6, 2005.
Sec. 20-633. Administration of influenza vaccine by licensed pharmacists.
Regulations. (a) On and after October 1, 2005, any person licensed as a pharmacist
under part II of this chapter may administer influenza vaccine to an adult, provided the
administration is conducted pursuant to the order of a licensed health care provider and
in accordance with the regulations established pursuant to subsection (b) of this section.
(b) Not later than September 1, 2005, the Commissioner of Consumer Protection, in
consultation with the Commissioner of Public Health and the Commission of Pharmacy,
shall adopt regulations, in accordance with chapter 54, to implement the provisions of
this section. Such regulations shall (1) require any pharmacist who administers influenza
vaccine to an adult pursuant to this section to successfully complete an immunization
training program for pharmacists; (2) define the basic requirements of such training
program, which shall include training and instruction in pre-administration education
and screening, vaccine storage and handling, subcutaneous and intramuscular injections,
recordkeeping, vaccine safety, cardiopulmonary resuscitation, basic cardiac life support
and adverse event reporting; (3) identify qualifying training programs, which are accredited by the National Centers for Disease Control Prevention, the Accreditation Council
for Pharmacy Education or other appropriate national accrediting body; and (4) establish
a system of control and reporting.
(c) For purposes of this section, "adult" means an individual who has attained the
age of eighteen years.
(P.A. 05-212, S. 6.)
History: P.A. 05-212 effective July 6, 2005.